Nabriva Therapeutics

Nabriva Therapeutics Plc is a biopharmaceutical company, which engages in the research, development, and commercialization of novel anti-infective agents to treat serious infections. Its product pipeline includes Lefamulin, CONTEPO, and BC-7013. The company was founded in October 2005 and is headquartered in Dublin, Ireland.

Earnings data Q1 2023

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Nabriva Therapeutics Plc is a biopharmaceutical company, which engages in the commercialization and development of novel anti-infective agents to treat infections. The company was founded in October 2005 and is headquartered in Dublin, Ireland.

DUBLIN, Ireland and FORT WASHINGTON, Pa., April 11, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, announced that the first patient was enrolled in a Phase 1 clinical trial to assess the safety and pharmacokinetics of oral and intravenous XENLETA® (lefamulin) in adult patients with cystic fibrosis (CF).

Nabriva Therapeutics Announces First Patient Enrolled in Phase 1 Trial of XENLETA® (lefamulin) in Adult Patients with Cystic Fibrosis

Nabriva Therapeutics plc (NBRV) CEO Ted Schroeder on Q4 2021 Results - Earnings Call Transcript

-Total revenue of $9.3 million driven by continued SIVEXTRO prescription growth-

Nabriva Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides a Corporate Update

DUBLIN, Ireland and FORT WASHINGTON, Pa., March 15, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it will report its fourth quarter and full year 2021 financial results along with recent company highlights after the close of the U.S. financial markets on Tuesday, March 29, 2022. Nabriva's management will host a conference call at 4:30 p.m. ET to discuss the financial results and recent corporate highlights.

Nabriva Therapeutics to Report 2021 Financial Results and Recent Corporate Highlights on March 29, 2022

DUBLIN, Ireland, March 01, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it has granted a non-statutory stock option to purchase an aggregate of 12,000 ordinary shares of Nabriva Therapeutics as an inducement to a newly hired employee. This grant was awarded pursuant to the Nasdaq inducement grant exception as a component of new hire employment compensation.

Nabriva Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

— Meeting to Reconvene on March 24, 2022 —

Nabriva Therapeutics Adjourns Extraordinary General Meeting of Shareholders on January 18, 2022

— Meeting to Reconvene on January 18, 2022 —

Nabriva Therapeutics Adjourns Extraordinary General Meeting of Shareholders

-SIVEXTRO ® (tedizolid phosphate) remains on track for return to historical peak sales by mid-2022-

Nabriva Therapeutics Provides Business Update and Announces Preliminary Financial Results for the Fourth Quarter of 2021

— Meeting to Reconvene on January 14, 2022 — — Meeting to Reconvene on January 14, 2022 —

Nabriva Therapeutics to Adjourn Extraordinary General Meeting of Shareholders on December 22, 2021

DUBLIN, Ireland and FORT WASHINGTON, Pa., Dec. 21, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that Ted Schroeder, Chief Executive Officer at Nabriva, will provide a company overview and business update at the H.C. Wainwright BioConnect Virtual Conference. The presentation will be available on-demand beginning on Monday, January 10 at 7:00am ET. Management will also host investor meetings January 10-13, 2022.

Nabriva Therapeutics to Present at the H.C. Wainwright BioConnect Virtual Conference

The heavy selling pressure might have exhausted for Nabriva Therapeutics AG (NBRV) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Nabriva Therapeutics AG (NBRV) Loses 37.6% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

DUBLIN, Ireland and FORT WASHINGTON, Pa., Nov. 29, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, announced today that its partner, Sumitomo Pharmaceuticals' (Suzhou) Co., Ltd., new drug application (NDA) to market oral and intravenous (IV) formulations of lefamulin for the treatment of community-acquired pneumonia (CAP) in adults in mainland China has been accepted for review by the Chinese Center for Drug Evaluation (CDE), China's regulatory authority, on November 23, 2021.

Lefamulin NDA Filed in Mainland China for Treatment of Community Acquired Pneumonia

Down 25.5% in 4 Weeks, Here's Why You Should You Buy the Dip in Nabriva Therapeutics AG (NBRV)

Nabriva Therapeutics (NBRV) has been struggling lately, but the selling pressure may be coming to an end soon.

Nabriva Therapeutics (NBRV) Sees Hammer Chart Pattern: Time to Buy?

10-count oral pack – or ‘X' pack allows for improved access and the opportunity to further expand retail availability 10-count oral pack – or ‘X' pack allows for improved access and the opportunity to further expand retail availability

Nabriva Announces Availability of XENLETA® (lefamulin) in a 10-Count Oral Pack

Nabriva Therapeutics PLC (NASDAQ: NBRV) has announced its Q3 2021 financial results. These are the details.

Nabriva Therapeutics (NBRV): Q3 2021 Financial Results

Nabriva Therapeutics plc (NBRV) CEO Theodore Schroeder on Q3 2021 Results - Earnings Call Transcript

-Revenues of $8.9 million increased 8% sequentially versus Q2 2021-

Nabriva Therapeutics Reports Third Quarter 2021 Financial Results and Provides a Corporate Update

DUBLIN, Ireland and FORT WASHINGTON, Pa., Nov. 05, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that Ted Schroeder, Chief Executive Officer at Nabriva, will provide a company overview and business update at the Jefferies London Healthcare Conference. The presentation will be available on-demand beginning on Thursday, November 18 at 8:00am GMT / 3:00am ET through Friday, November 19 at 5:00pm GMT / 12:00pm ET. Management will host investor meetings on Thursday and Friday, November 18-19, 2021.

Nabriva Therapeutics to Present at the Jefferies London Healthcare Conference

DUBLIN, Ireland, Oct. 26, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it will report its third quarter financial results along with recent company highlights after the close of the U.S. financial markets on Tuesday, November 9, 2021. Nabriva's management will host a conference call at 4:30 p.m. ET to discuss the financial results and recent corporate highlights.

Nabriva Therapeutics to Report Third Quarter 2021 Financial Results and Recent Corporate Highlights on November 9, 2021

DUBLIN, Ireland and FORT WASHINGTON, Pa., Oct. 15, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today, announced data presentation at CHEST 2021, the annual meeting of the American College of CHEST Physicians, which will be held virtually October 17-20.

Nabriva Therapeutics to Present Data at CHEST Annual Meeting 2021

DUBLIN, Ireland and FORT WASHINGTON, Pa., Oct. 04, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today published the first data to demonstrate the anti-inflammatory activity of XENLETA® (lefamulin).

Nabriva Publishes Data Demonstrating the Potent Anti-Inflammatory Properties of XENLETA® (lefamulin)

DUBLIN, Ireland and FORT WASHINGTON, Pa., Oct. 01, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, announced the appointment of Dr. Christine Guico-Pabia, M.D., MBA, MPH as Chief Medical Officer (CMO) effective October 1, 2021.

Nabriva Therapeutics Appoints Dr. Christine Guico-Pabia, M.D., as Chief Medical Officer

Acurx Pharmaceuticals LLC

Cidara Therapeutics

Iterum Therapeutics Plc

Melinta Therapeutics

Paratek Pharma

SCYNEXIS

Summit Therapeutics

WASHINGTON, Sept. 30, 2021 /PRNewswire/ -- The Antimicrobials Working Group (AWG), a coalition of companies with the mission to combat drug resistant infections and spur life-saving innovations, today announced that 10 of its member companies will present data from their clinical and research programs at IDWeek 2021 taking place virtually from September 29-October 3, 2021.

Antimicrobials Working Group Highlights Member Company Participation at IDWeek 2021

DUBLIN, Ireland and FORT WASHINGTON, Pa., Sept. 24, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced data presentation at the Infectious Disease Society of America (IDSA) IDWeek™ 2021, taking place virtually from September 29 – October 3, 2021.

News for Nabriva Therapeutics Stock (NBRV)